Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)
Conditions: Arterial Hypertension; HTN Interventions: Drug: Amlodipine 5 mg + indapamide 1.25 mg + perindopril 5 mg; Drug: Amlodipine 5 mg + indapamide 2.5 mg + perindopril 10 mg; Drug: Amlodipine 10 mg + indapamide 2.5 mg + perindopril 10 mg Sponsors: Servier Russia Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials
Initial treatment with a single capsule containing half-dose quadruple therapy versus standard-dose dual therapy in hypertensive patients (QUADUAL): statistical analysis plan for a randomized, blinded, crossover trial
DiscussionThis statistical analysis plan will be confirmed prior to blind review and data lock before un-blinding and is sought to increase the validity of the QUADUAL trial.Trial registrationClinicalTrials.gov, NCT05377203. Registered May 11, 2022,https://clinicaltrials.gov/study/NCT05377203. (Source: Trials)
Source: Trials - January 13, 2024 Category: Research Source Type: clinical trials
Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention
Conditions: Kidney Stone Interventions: Drug: Indapamide 2.5 MG; Drug: Hydrochlorothiazide 50Mg; Drug: Chlorthalidone 25mg Sponsors: Insel Gruppe AG, University Hospital Bern; University of Bern Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials
Bioequivalence Study of Perindopril /Amlodipine/Indapamide 8 mg (10 mg)/2.5 mg/10 mg Tablets in Healthy Volunteers Under Fasting Conditions
Condition: Bioequivalence Intervention: Drug: Perindopril/Indapamide/Amlodipine 8 mg/2.5 mg/10 mg tablet / Triplixam® 10 mg/2.5 mg/10 mg tablet Sponsor: Pharmtechnology LLC Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 11, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy
Condition: Essential Hypertension Interventions: Drug: Fimasartan + Indapamide; Drug: Fimasartan + Indapamide placebo Sponsor: Boryung Pharmaceutical Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2023 Category: Research Source Type: clinical trials
